Canaccord raised the firm’s price target on ShockWave Medical to $263 from $215 and keeps a Buy rating on the shares. The firm said they reported better than expected results and raised the target to reflect a higher premium to the comp group and increased comp group multiples.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on SWAV:
- Shockwave Medical Reports Fourth Quarter and Full Year 2023 Financial Results
- SWAV Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Shockwave Medical Announces Regulation FD Disclosure Update
- Shockwave Medical Names Renee Gaeta New CFO
- Shockwave Medical Appoints Renee Gaeta as Chief Financial Officer
